PEGBIO CO-B (02565) announced that on December 12, 2025 (after trading hours), the company entered into a placement agreement with joint placement agents. Under the agreement, the company conditionally agreed to place a total of 5.136 million shares at HK$58.41 per share to no fewer than six placees on a best-efforts basis. These shares will be issued under the general mandate in accordance with the terms of the placement agreement.

Assuming no changes in the company’s issued share capital from the announcement date to the completion date, the 5.136 million placement shares represent: (i) approximately 1.84% of the issued H-shares and 1.33% of the total issued shares as of the announcement date; and (ii) approximately 1.81% of the enlarged H-shares and 1.31% of the total shares post-placement.

The placement price of HK$58.41 per share represents a 10% discount to the closing price of HK$64.90 per H-share on the Hong Kong Stock Exchange on December 12, 2025 (the date of the placement agreement).

If all placement shares are fully subscribed, the estimated gross proceeds and net proceeds (after deducting related costs and expenses) will be approximately HK$300 million and HK$296 million, respectively. The net proceeds will be allocated as follows: 1. Approximately 40% for building a next-generation intelligent R&D and data platform; 2. Approximately 28% for loan repayment and strengthening the company’s capital structure; 3. Approximately 12% for ongoing and planned R&D of PB-2301 and PB-2309; 4. Approximately 10% for establishing a Hong Kong subsidiary and accelerating overseas business expansion; 5. Approximately 10% for general corporate purposes and working capital.